Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
Although the incidence of myocarditis or pericarditis following mRNA COVID-19 vaccination is low, a two- to threefold higher likelihood is seen among individuals who received mRNA-1273 compared to BNT162b2 vaccine, reveals a study.
Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
26 Nov 2022
Lower all-cause death, fewer HF events with empagliflozin in acute HF
Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022.
Lower all-cause death, fewer HF events with empagliflozin in acute HF
25 Nov 2022
Extended-release morphine of no benefit to COPD patients with breathlessness
A week-long treatment course of low-dose, extended-release morphine does not appear to be effective at relieving breathlessness in patients with chronic obstructive pulmonary disease (COPD), according to a study.
Extended-release morphine of no benefit to COPD patients with breathlessness
25 Nov 2022
Immunosuppressant exposure tied to guideline-congruent cervical cancer screening
Guideline-congruent screening for cervical cancer remains poor in women with systemic lupus erythematosus (SLE), according to a study.
Immunosuppressant exposure tied to guideline-congruent cervical cancer screening
24 Nov 2022
GLP-1 receptor agonists halt COPD exacerbations in T2D patients
Use of glucagon-like peptide 1 (GLP-1) receptor agonists or sodium-glucose co-transporter-2 (SGLT-2) inhibitors, compared with sulfonylureas, helps prevent severe exacerbations of chronic obstructive pulmonary disease (COPD) in patients with type 2 diabetes (T2D), a UK study has shown.
GLP-1 receptor agonists halt COPD exacerbations in T2D patients
23 Nov 2022
Anifrolumab for SLE shows favourable benefit–risk profile in extension study
Patients with moderate-to-severe systemic lupus erythematosus (SLE) appear to fare well with anifrolumab, with a recent study showing that the drug has an acceptable long-term safety profile and helps maintain reductions in disease activity and glucocorticoid usage.
